PGP and cancer: All of these results confirm that elacridar inhibits P-gp activity and sensitizes drug-resistant cancer cells to cytotoxic drugs that are P-gp substrates, suggesting that elacridar can be a good candidate for an anticancer drug to increase chemotherapy effectiveness.